Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.
The company will be the first to take a FcRH5-targeting project into phase 3.
Like Orserdu, giredestrant works in all-comers in an ESR1m-enriched trial.
Big pharma interest remains, but the mood is fast turning gloomy.
